3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
307
Recurrence
64
Neoplasms
32
Neoplasms, Plasma Cell
17
Lymphoma, Non-Hodgkin
14
Carcinoma, Non-Small-Cell Lung
13
Prostatic Neoplasms
12
Vomiting
11
Neoplasm Metastasis
8
Leukemia, Myeloid, Acute
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Nausea
7
Lymphoma, Large B-Cell, Diffuse
7
Lymphoma
7
Ovarian Neoplasms
6
Immunoglobulin Light-chain Amyloidosis
6
Hematologic Neoplasms
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Paraproteinemias
5
Lung Neoplasms
5
Leukemia
5
Small Cell Lung Carcinoma
4
Renal Insufficiency
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Plasmacytoma
4
Lymphoma, Follicular
4
Hematologic Diseases
4
Leukemia, Plasma Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Breast Neoplasms
3
Interventions
enzalutamide
14
Docetaxel
7
radium Ra 223 dichloride
6
Abiraterone Acetate
6
Prednisone
5
darolutamide
4
abiraterone
3
olaparib
2
niraparib
2
atezolizumab
2
apalutamide
2
zimberelimab
1
xentuzumab
1
tasquinimod
1
sacituzumab govitecan
1
sabizabulin
1
quemliclustat
1
ipatasertib
1
ibrutinib
1
gedatolisib
1
gallium 68 PSMA-11
1
fludrocortisone acetate
1
cabazitaxel
1
Rosuvastatin Calcium
1
Radium-223
1
Pluvicto
1
Pioglitazone
1
Nivolumab
1
JNJ-64619178
1
JNJ-64264681
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Prostatic Neoplasms, Castration-Resistant
×
Dexamethasone
×
Clear all
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled